⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29637512 | 0.81 | — | — | |
| SCHEMBL4053901 | 0.81 | — | — | |
| SCHEMBL207537 | 0.77 | — | — | |
| SCHEMBL29739386 | 0.77 | — | — | |
| SCHEMBL20772455 | 0.77 | — | — | |
| SCHEMBL29849906 | 0.77 | — | — | |
| SCHEMBL19532041 | 0.77 | PDPK1 (0.44) | — | |
| SCHEMBL29567534 | 0.77 | PDPK1 (0.44) | — | |
| SCHEMBL191637 | 0.75 | — | — | |
| SCHEMBL13016652 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112867716-A | Solid forms of FGFR inhibitors and methods for their preparation | 因赛特公司 | 2021-05-28 | — | — | CN | claimed |
| EP-3788047-A2 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | Incyte Corporation (US) | 2021-03-10 | — | — | EP | claimed |
| US-20190337948-A1 | SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME | WILMINGTON PHARMATECH | 2019-11-07 | — | — | US | claimed |
| WO-2015157360-A1 | PROCESSES TO MAKE PROTEIN KINASE INHIBITORS | ABBVIE INC. (US) | 2015-10-15 | — | — | WO | claimed |
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026090330-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4121423-B1 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108521-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2026-04-23 | — | — | US | disclosed |
| EP-4724440-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | Interline Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4702021-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-12552792-B2 | Solid forms of an FGFR inhibitor and processes for preparing the same | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4665453-A1 | GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| CN-101389622-A | Pyrimidine derivatives used as pi-3 kinase inhibitors | NOVARTIS AG (CH) | 2009-03-18 | — | — | CN | disclosed |
| EP-1984350-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084786-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |